Summarized by Masters of Longevity from Nature - Biotechnology.
A review of strategies to improve antibody delivery across the blood–brain barrier for Alzheimer’s therapies, covering non‑invasive and targeted shuttle approaches.
Key Takeaways
- The antibodies currently approved by the FDA for AD treatment, Lecanemab and Donanemab, target amyloid beta (Aβ) 6.
- Aβ is an extracellular protein produced from amyloid precursor protein (APP) when it is cleaved by a β-secretase, such as BACE1, then by a γ-secretase 7 , 8.
- Antibodies and small-molecule inhibitors targeting BACE1 have been explored, but they have not been successful in slowing cognitive decline in humans (clinical trials: NCT01561430, NCT02260674, NCT01739348, NCT03131453, NCT02322021, NCT02245737) 6 , 9.
